According to a meta-analysis, the global prevalence of SPG is 1.8/100,000, with SPG3A, SPG4, and SPG11 subtypes predominating in registered cases and being infrequently diagnosed in consanguineous settings [3,4]. This evidence concerns the gene SPG11 and hereditary spastic paraplegia.